Open AccessUnlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*
Author(s) -
Sebastian Rehberg,
Perenlei Enkhbaatar,
Janina Rehberg,
Erin La,
Nicky Ferdyan,
Steve Qi,
Kazimierz Wiśniewski,
Lillian D. Traber,
Claudio D. Schteingart,
Pierre Rivière,
Régent Laporte,
Daniel L. Traber
Publication year - 2012
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0b013e31824e0fe5
Subject(s) - vasopressin , agonist , medicine , endocrinology , arginine vasopressin receptor 1b , vasopressin receptor , desmopressin , arginine vasopressin receptor 2 , arginine , receptor , chemistry , antagonist , biochemistry , amino acid
To compare the effects on von Willebrand factor release of the mixed vasopressin type 1a and type 2 receptor agonist arginine vasopressin and the selective vasopressin type 1a receptor agonist FE 202158, [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin, at doses required for the treatment of septic shock.